Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study.

Find People
Find Everything
About This Site
Edit My Profile
Login to Profiles
DIRECT2Experts
Help / FAQ

Announcement

You can now add alternative names! Click here to add other names that you've published under.

Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study.

Wu CE, Chang CF, Huang CY, Yang CT, Kuo CS, Hsu PC, Chang JW. Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. BMC Cancer. 2021 Jul 27; 21(1):859.

View in: PubMed

subject areas

Aged
Aged, 80 and over
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Disease Management
Female
Humans
Kaplan-Meier Estimate
Lung Neoplasms
Male
Middle Aged
Molecular Targeted Therapy
Mutation
Neoplasm Staging
Prognosis
Protein Kinase Inhibitors
Retrospective Studies
Treatment Outcome

authors with profiles

Ping-Ching Hsu